Overview

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Status:
Recruiting

Trial end date:
2024-04-15

Target enrollment:

Participant gender:

Summary

This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

Iqvia Pty Ltd

Treatments:

Benralizumab